Rubius Therapeutics (NASDAQ:RUBY – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Institutional & Insider Ownership

76.1% of Rubius Therapeutics shares are held by institutional investors. Comparatively, 88.9% of Vigil Neuroscience shares are held by institutional investors. 5.3% of Rubius Therapeutics shares are held by insiders. Comparatively, 46.6% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Rubius Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.41, meaning that its share price is 241% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Rubius Therapeutics and Vigil Neuroscience, as reported by MarketBeat.

Rubius Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 37,995.24%. Vigil Neuroscience has a consensus target price of $18.80, suggesting a potential upside of 97.48%. Given Rubius Therapeutics' higher probable upside, equities research analysts plainly believe Rubius Therapeutics is more favorable than Vigil Neuroscience.

Valuation and Earnings

This table compares Rubius Therapeutics and Vigil Neuroscience's top-line revenue, earnings per share (EPS) and valuation.

Vigil Neuroscience is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rubius Therapeutics and Vigil Neuroscience's net margins, return on equity and return on assets.

Summary

Vigil Neuroscience beats Rubius Therapeutics on 9 of the 11 factors compared between the two stocks.

About Rubius Therapeutics

(Get Rating)

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.

About Vigil Neuroscience

(Get Rating)

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.